Skip to Content

Baxter International Inc

BAX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$73.00VdbktmKgqgzczx

Easing Pressures Should Boost Baxter's Prospects, Especially in 2025 and Beyond

Business Strategy and Outlook

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. We see these external pressures easing. Also, we suspect Baxter's financial prospects will improve, especially in 2025 and beyond, as hospitals renegotiate their reimbursement deals with third-party payers, and as Baxter renegotiates significant contracts, a key group purchasing organization among them.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BAX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center